On the uses of genetic information in disease: An opinionated take on NEJM highlights for December 2018
Marc Herant
January 3, 2019
Genetic trade secrets In 2012, the US Supreme Court decided a case known as “Prometheus” establishing that therapeutic methods based on biomarkers were not patentable – this essentially blocked one of the two main avenues to monetizing intellectual property from the very hard clinical work of figuring out personalized medicine, i.e. what works for whom. The other avenue that would remain is that of trade secrets, and I for one, have been waiting for the other shoe to drop. A hint comes from a study on ovarian cancer just published